Its Stock Has Paid Off Big Time For Novavax, Inc.

With 56.27 million shares changed hands, the volume of the stock remained heavier than its average volume of 11.31 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $15.0 whereas the lowest price it dropped to was $12.56. The 52-week range on NVAX shows that it touched its highest point at $13.97 and its lowest point at $3.53 during that stretch. It currently has a 1-year price target of $18.00. Beta for the stock currently stands at 1.73.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NVAX was up-trending over the past week, with a rise of 192.41%, but this was up by 227.18% over a month. Three-month performance surged to 245.64% while six-month performance rose 116.03%. The stock gained 59.53% in the past year, while it has gained 180.83% so far this year. A look at the trailing 12-month EPS for NVAX yields -3.18 with Next year EPS estimates of -0.55. For the next quarter, that number is 0.20. This implies an EPS growth rate of 101.17% for this year and -968.43% for next year.

Float and Shares Shorts:

At present, 139.51 million NVAX shares are outstanding with a float of 133.40 million shares on hand for trading. On 2024-04-30, short shares totaled 44.93 million, which was 3200.0 higher than short shares on 1711584000. In addition to Mr. John Charles Jacobs M.B.A. as the firm’s President, CEO & Director, Mr. John Joseph Trizzino B.S., M.B.A. serves as its President & COO.

Institutional Ownership:

Through their ownership of 0.60441 of NVAX’s outstanding shares, institutional investors have minority control over the company.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-03-31, NVAX reported revenue of $93855000.0 and operating income of -$144831000.0. The EBITDA in the recently reported quarter was -$129030000.0 and diluted EPS was -$1.05.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NVAX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.